Related Experiment Videos
1Abteilung für Klinische Pharmakokinetik, Universitätsklinik für Klinische Pharmakologie, Universität Wien.
Abstract:
The major challenges in clinical oncological drug studies are to detect promising drug candidates early on in clinical drug development and to protect patients from adverse drug reactions of ineffective drugs. These challenges are met in the classical concept of clinical oncological drug trials in three phases. The aim of the present article is to provide a concise and comprehensive overview of the scientific logic of these 3 phases. Recent progress in the conception of clinical oncological drug studies was made in particular in phase I where the implementation of novel dose escalation procedures has led to a speeding up of phase I and an increase in the number of patients that receive an experimental drug in the therapeutic concentration range. However, the classical 3-phase concept of clinical oncological drug trials can not be transposed to trials with some novel anticancer drugs without critical reappraisal. It is therefore expected that this classical concept will undergo specific modifications in the near future. Copyright 2000 S. Karger GmbH, Freiburg
Insights
Clinical oncological drug studies face challenges in early detection and patient safety. This article reviews the traditional three-phase trial concept, noting recent advancements in Phase I and potential modifications for novel anticancer drugs.
Area of Science:
- Oncology
- Clinical Pharmacology
- Drug Development
Background:
- Clinical oncological drug studies aim to identify effective cancer drug candidates early and minimize patient risk from ineffective treatments.
- The traditional three-phase clinical trial model is the established framework for addressing these challenges in oncology drug development.
Purpose of the Study:
- To provide a concise overview of the scientific logic underpinning the three phases of clinical oncological drug trials.
- To discuss recent advancements and potential future modifications to the classical trial design.
Main Methods:
- Review of the established three-phase clinical trial concept in oncology.
- Analysis of recent progress, particularly in Phase I dose escalation procedures.
- Discussion on the applicability of the classical model to novel anticancer agents.
Main Results:
- Recent innovations in Phase I trials, such as novel dose escalation methods, have accelerated the phase and increased patient exposure to therapeutic drug concentrations.
- The classical three-phase model may require critical reassessment for its suitability with certain novel anticancer drugs.
Conclusions:
- The traditional three-phase clinical trial structure is fundamental to oncological drug development.
- Adaptations to the classical model are anticipated to accommodate the unique characteristics of emerging anticancer therapies, ensuring continued progress in cancer treatment.